Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Oxonic Acid"" wg kryterium: Temat


Tytuł :
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Autorzy :
Jiang Z; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sun Y; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang W; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cui C; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang L; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhou A; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło :
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Jun; Vol. 16 (3), pp. 180-186. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Capecitabine/*therapeutic use
Chemotherapy, Adjuvant/*methods
Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Tegafur/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Capecitabine/pharmacology ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oxaliplatin/pharmacology ; Oxonic Acid/pharmacology ; Retrospective Studies ; Stomach Neoplasms/pathology ; Survival Rate ; Tegafur/pharmacology
Czasopismo naukowe
Tytuł :
A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy.
Autorzy :
Shoji T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan. .
Takeshita R; Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, 2 Nakaaketo, Tamonoki, Hachinohe, Aomori, 039-1104, Japan.
Saito T; Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, 2 Nakaaketo, Tamonoki, Hachinohe, Aomori, 039-1104, Japan.
Aida T; Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, 2 Nakaaketo, Tamonoki, Hachinohe, Aomori, 039-1104, Japan.
Sasou S; Department of Pathology and Laboratory, Hachinohe Red Cross Hospital, 2 Nakaaketo, Tamonoki, Hachinohe, Aomori, 039-1104, Japan.
Baba T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan.
Pokaż więcej
Źródło :
Journal of ovarian research [J Ovarian Res] 2020 Mar 21; Vol. 13 (1), pp. 33. Date of Electronic Publication: 2020 Mar 21.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Carcinoma, Signet Ring Cell/*diagnosis
Carcinoma, Signet Ring Cell/*drug therapy
Ovarian Neoplasms/*diagnosis
Ovarian Neoplasms/*drug therapy
Oxonic Acid/*therapeutic use
Tegafur/*therapeutic use
Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Biomarkers, Tumor ; Biopsy ; Carcinoma, Signet Ring Cell/etiology ; Drug Combinations ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Ovarian Neoplasms/etiology ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Tomography, X-Ray Computed ; Treatment Outcome ; Ultrasonography/methods
Czasopismo naukowe
Tytuł :
Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats.
Autorzy :
Dera AA; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.; Central Research Laboratory, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Rajagopalan P; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.; Central Research Laboratory, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Alfhili MA; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Ahmed I; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.; Central Research Laboratory, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Chandramoorthy HC; Department of Microbiology & Clinical Parasitology and Centre for Stem Cell Research, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Pokaż więcej
Źródło :
BioFactors (Oxford, England) [Biofactors] 2020 Mar; Vol. 46 (2), pp. 292-300. Date of Electronic Publication: 2019 Nov 23.
Typ publikacji :
Journal Article
MeSH Terms :
Oxonic Acid*
Benzoquinones/*therapeutic use
Hyperuricemia/*complications
Kidney Diseases/*etiology
Kidney Diseases/*prevention & control
Oxidative Stress/*drug effects
Animals ; Disease Models, Animal ; Kidney/drug effects ; Male ; Mitochondria/drug effects ; Rats ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł :
S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.
Autorzy :
Lai CL; Division of Pulmonology and Critical Care, Department of Internal Medicine, Buddhish Dalin Tzu Chi Hospital, Chiayi, Taiwan.; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan.; Institute of Molecular Biology, Department of Life Science, National Chung Cheng University, Chiayi, Taiwan.
Wei YF; Division of Respiratory and Chest Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan.; Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan.
Hsia TC; Department of Respiratory Therapy, China Medical University Hospital, Taichung, Taiwan.
Chang GC; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan and Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Wu JT; Division of Respiratory and Chest Medicine, E-Da Cancer Hospital/I-Shou University, Kaohsiung, Taiwan.
Chen JY; Division of Respiratory and Chest Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan.
Chen YM; Department of Chest Medicine, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Pokaż więcej
Źródło :
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Apr; Vol. 16 (2), pp. e68-e73. Date of Electronic Publication: 2019 Nov 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Cisplatin/*therapeutic use
Lung Neoplasms/*drug therapy
Oxonic Acid/*therapeutic use
Tegafur/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cisplatin/pharmacology ; Drug Combinations ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Oxonic Acid/pharmacology ; Survival Analysis ; Taiwan ; Tegafur/pharmacology
Czasopismo naukowe
Tytuł :
Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Autorzy :
Watanabe H; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Hayashi T; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Komori K; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Hara K; Department of Surgery, Yokohama City University, Yokohama, Japan.
Maezawa Y; Department of Gastric Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Kano K; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Shimoda Y; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Fujikawa H; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Aoyama T; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yamada T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yamamoto N; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Cho H; Department of Gastric Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Ito H; Department of Respiratory Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Shiozawa M; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yukawa N; Department of Surgery, Yokohama City University, Yokohama, Japan.
Morinaga S; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yoshikawa T; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Rino Y; Department of Surgery, Yokohama City University, Yokohama, Japan.
Masuda M; Department of Surgery, Yokohama City University, Yokohama, Japan.
Ogata T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Oshima T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Mar; Vol. 40 (3), pp. 1683-1690.
Typ publikacji :
Journal Article
MeSH Terms :
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*complications
Stomach Neoplasms/*drug therapy
Tegafur/*therapeutic use
Chemotherapy, Adjuvant ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oxonic Acid/pharmacology ; Postoperative Complications ; Prognosis ; Stomach Neoplasms/pathology ; Tegafur/pharmacology
Czasopismo naukowe
Tytuł :
Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Autorzy :
Okamura Y; Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Yasukawa S; Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Narimatsu H; Cancer Prevention and Control Division, Kanagawa Cancer Center, Yokohama, Japan.
Boku N; Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Fukutomi A; Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Konishi M; Hepato-Biliary-Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Morinaga S; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Toyama H; Hepato-Biliary-Pancreatic Surgery, Kobe University, Kobe, Japan.
Kaneoka Y; Surgery, Ogaki Municipal Hospital, Ogaki, Japan.
Shimizu Y; Gastrointestinal Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Nakamori S; Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Sata N; Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Japan.
Yamakita K; Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Takahashi A; Gastrointestinal Surgery, Saitama Cancer Center, Saitama, Japan.
Kainuma O; Gastrointestinal Surgery, Chiba Cancer Center, Chiba, Japan.
Hishinuma S; Surgery, Tochigi Cancer Center, Utsunomiya, Japan.
Yamaguchi R; Surgery, Kasugai Municipal Hospital, Kasugai, Japan.
Nagino M; Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate of School of Medicine, Nagoya, Japan.
Hirano S; Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yanagisawa A; Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mori K; Clinical Trial Coordination Office Biostatistician, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Uesaka K; Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Feb; Vol. 111 (2), pp. 548-560. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*administration & dosage
Equilibrative Nucleoside Transporter 1/*metabolism
Oxonic Acid/*administration & dosage
Pancreatectomy/*methods
Pancreatic Neoplasms/*therapy
Tegafur/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/pharmacology ; Biomarkers, Tumor/metabolism ; Chemotherapy, Adjuvant ; Clinical Trials, Phase I as Topic ; Dihydrouracil Dehydrogenase (NADP)/metabolism ; Drug Combinations ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Middle Aged ; Oxonic Acid/pharmacology ; Pancreatic Neoplasms/metabolism ; Prognosis ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Survival Analysis ; Tegafur/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Autorzy :
Liao W; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Huang J; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Zhu G; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhou J; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Wen F; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Zhang P; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Zhou K; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Wu Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Wang X; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Gou H; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Li Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; West China Biomedical Big Data Center, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2020 Feb; Vol. 20 (1), pp. 133-138. Date of Electronic Publication: 2019 Oct 10.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antimetabolites, Antineoplastic/*administration & dosage
Deoxycytidine/*analogs & derivatives
Oxonic Acid/*administration & dosage
Pancreatic Neoplasms/*therapy
Tegafur/*administration & dosage
Antimetabolites, Antineoplastic/economics ; Combined Modality Therapy ; Cost-Benefit Analysis ; Deoxycytidine/administration & dosage ; Deoxycytidine/economics ; Disease-Free Survival ; Drug Combinations ; Humans ; Neoplasm Recurrence, Local ; Oxonic Acid/economics ; Pancreatic Neoplasms/economics ; Pancreatic Neoplasms/pathology ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Tegafur/economics
Czasopismo naukowe
Tytuł :
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Autorzy :
Nakamura M; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan, .
Ojima T; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Katsuda M; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Hayata K; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Kitadani J; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Nakamori M; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Yamaue H; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Pokaż więcej
Źródło :
Oncology [Oncology] 2021; Vol. 99 (1), pp. 57-61. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Peritoneal Neoplasms/*drug therapy
Stomach Neoplasms/*drug therapy
Aged ; Albumins/administration & dosage ; Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dose-Response Relationship, Drug ; Drug Combinations ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Myocardial Infarction/chemically induced ; Myocardial Infarction/pathology ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Peritoneal Neoplasms/pathology ; Peritoneal Neoplasms/secondary ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe
Tytuł :
The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.
Autorzy :
Yan L; Department of General Surgery, 940th Hospital of Joint Logistics Support Force, Lanzhou, Gansu, China.
Liu H
Li H
Han X
Cao T
Wang C
Li G
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2019 Nov; Vol. 98 (44), pp. e17605.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Tegafur/*therapeutic use
Administration, Oral ; Adult ; Aged ; Chemotherapy, Adjuvant ; Drug Combinations ; Feasibility Studies ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Postoperative Period ; Retrospective Studies ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Survival Analysis ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe
Tytuł :
Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Autorzy :
Chen Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Zhao Z; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Li Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Yang Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Li L; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Jiang Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Lin C; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Cao Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Zhou P; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Tian Y; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Wu T; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China. Electronic address: .
Pang J; Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China. Electronic address: .
Pokaż więcej
Źródło :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2021 Jan; Vol. 80, pp. 153374. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Journal Article
MeSH Terms :
Flavanones/*pharmacology
Hyperuricemia/*drug therapy
Uric Acid/*urine
Xanthine Oxidase/*antagonists & inhibitors
Animals ; Antioxidants/pharmacology ; Disease Models, Animal ; Enzyme Inhibitors/pharmacology ; Flavanones/chemistry ; Flavanones/metabolism ; Glucose Transport Proteins, Facilitative/chemistry ; Glucose Transport Proteins, Facilitative/genetics ; Glucose Transport Proteins, Facilitative/metabolism ; HEK293 Cells ; Humans ; Hyperuricemia/chemically induced ; Kidney/drug effects ; Kidney/metabolism ; Liver/drug effects ; Male ; Mice ; Molecular Docking Simulation ; Organic Anion Transporters/chemistry ; Organic Anion Transporters/genetics ; Organic Anion Transporters/metabolism ; Organic Cation Transport Proteins/chemistry ; Organic Cation Transport Proteins/genetics ; Organic Cation Transport Proteins/metabolism ; Oxonic Acid/toxicity ; Uric Acid/blood
Czasopismo naukowe
Tytuł :
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Autorzy :
Chiang NJ; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Tsai KK; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan.
Hsiao CF; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
Yang SH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Hsiao HH; Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan.
Shen WC; Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Hsu C; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Lin YL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen JS; Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Shan YS; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan.
Chen LT; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Jan; Vol. 124, pp. 123-130. Date of Electronic Publication: 2019 Nov 22.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Pancreatic Ductal/*drug therapy
Deoxycytidine/*analogs & derivatives
Leucovorin/*therapeutic use
Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Tegafur/*therapeutic use
Adenocarcinoma/pathology ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carcinoma, Pancreatic Ductal/pathology ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Combinations ; Female ; Humans ; Leucovorin/pharmacology ; Male ; Middle Aged ; Neoplasm Metastasis ; Oxaliplatin/pharmacology ; Oxonic Acid/pharmacology ; Pancreatic Neoplasms/pathology ; Tegafur/pharmacology
Czasopismo naukowe
Tytuł :
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Autorzy :
Nara S; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Esaki M; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ban D; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takamoto T; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shimada K; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ioka T; Oncology Center, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi Ube-shi, Yamaguchi, 755-8505, Japan.
Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ishii H; Division of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan.
Furuse J; Department of Medical Oncology, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2020 Dec 16; Vol. 50 (12), pp. 1353-1363.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Biliary Tract Neoplasms/classification ; Biliary Tract Neoplasms/pathology ; Biliary Tract Neoplasms/surgery ; Capecitabine/therapeutic use ; Chemotherapy, Adjuvant ; Cisplatin/therapeutic use ; Clinical Trials as Topic ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Drug Combinations ; Humans ; Neoadjuvant Therapy ; Oxonic Acid/therapeutic use ; Tegafur/therapeutic use
Czasopismo naukowe
Tytuł :
[Salvage Surgery for Unresectable Advanced Esophagogastric Junction Carcinoma with Multiple Liver Metastases after Successful Second-Line Treatment with Nab-Paclitaxel and Ramucirumab Following a Refractory Response to S-1 plus CDDP Therapy-A Case Report].
Autorzy :
Fujita T; Dept. of Gastroenterological Surgery, Takamatsu Hospital.
Shimizu Y
Dongping F
Yamamoto N
Kobayashi M
Iwabu H
Tsuji A
Pokaż więcej
Źródło :
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2020 Nov; Vol. 47 (11), pp. 1597-1600.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Liver Neoplasms*/drug therapy
Liver Neoplasms*/surgery
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/surgery
Albumins ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/therapeutic use ; Drug Combinations ; Esophagogastric Junction/surgery ; Gastrectomy ; Humans ; Male ; Middle Aged ; Oxonic Acid/therapeutic use ; Paclitaxel ; Positron Emission Tomography Computed Tomography ; Tegafur/therapeutic use
Czasopismo naukowe
Tytuł :
ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer.
Autorzy :
Uemura T; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.; Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Oguri T; Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. .
Maeno K; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Sone K; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Takeuchi A; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Fukuda S; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Kunii E; Department of Respiratory Medicine, Nagoya City West Medical Center, 1-1-1, Hirate-cho, Kita-ku, Nagoya, 462-8508, Japan.
Takakuwa O; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Kanemitsu Y; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Ohkubo H; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Takemura M; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Ito Y; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Niimi A; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Dec; Vol. 84 (6), pp. 1229-1239. Date of Electronic Publication: 2019 Sep 17.
Typ publikacji :
Journal Article
MeSH Terms :
ATP-Binding Cassette Transporters/*genetics
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Oxonic Acid/*pharmacology
Tegafur/*pharmacology
Administration, Oral ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Drug Combinations ; Drug Resistance, Neoplasm/genetics ; Feasibility Studies ; Female ; HeLa Cells ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Oxonic Acid/therapeutic use ; Polymorphism, Single Nucleotide ; Prognosis ; Tegafur/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study).
Autorzy :
Aisu N; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Yoshida Y; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan. .
Komono A; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Sakamoto R; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Kojima D; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Hasegawa S; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2019 Nov 12; Vol. 9 (1), pp. 16568. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Perioperative Care*
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*surgery
Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Tegafur/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant ; Colorectal Neoplasms/pathology ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Oxaliplatin/adverse effects ; Oxonic Acid/adverse effects ; Patient Compliance ; Survival Analysis ; Tegafur/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Autorzy :
Iwasa T; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayam, Japan.
Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. .
Watanabe S; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayam, Japan.
Kato R; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayam, Japan.
Mizuno Y; Department of Breast Surgery, Yokkaichi Municipal Hospital, Osakasayam, Japan.
Kojima Y; Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Osakasayam, Japan.
Takashima T; Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Yokkaichi, Japan.
Matsunami N; Department of Breast Surgery, Osaka Rosai Hospital, Kawasaki, Japan.
Morimoto T; Department of Breast Surgery, Yao Municipal Hospital, Osaka, Japan.
Yamamura J; Department of Surgery, Breast Oncology, Sakai City Medical Center, Sakai, Japan.
Ohtani S; Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Sakai, Japan.
Tanabe Y; Department of Medical Oncology, Toranomon Hospital, Sakai, Japan.
Yoshinami T; Department of Breast and Endocrine Surgery, Graduate school of medicine Osaka University, Hiroshima, Japan.
Takano T; Department of Medical Oncology, Toranomon Hospital, Sakai, Japan.
Komoike Y; Department of Breast and Endocrine Surgery, Kindai University Faculty of Medicine, Tokyo, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayam, Japan.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2019 Oct 16; Vol. 19 (1), pp. 962. Date of Electronic Publication: 2019 Oct 16.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Furans/*therapeutic use
Ketones/*therapeutic use
Oxonic Acid/*therapeutic use
Tegafur/*therapeutic use
Adult ; Aged ; Anthracyclines/therapeutic use ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged-Ring Compounds/therapeutic use ; Disease-Free Survival ; Drug Combinations ; Female ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Middle Aged ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Taxoids/therapeutic use ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe
Tytuł :
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Autorzy :
Zheng S; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China. .
Zhou Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Sun Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Wang Z; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Lu Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Oct; Vol. 84 (4), pp. 819-827. Date of Electronic Publication: 2019 Aug 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Capecitabine*/administration & dosage
Capecitabine*/adverse effects
Oxaloacetates*/administration & dosage
Oxaloacetates*/adverse effects
Oxonic Acid*/administration & dosage
Oxonic Acid*/adverse effects
Tegafur*/administration & dosage
Tegafur*/adverse effects
Gastrectomy/*methods
Stomach Neoplasms/*drug therapy
Chemotherapy, Adjuvant/methods ; China/epidemiology ; Cohort Studies ; Disease-Free Survival ; Drug Combinations ; Female ; Hand-Foot Syndrome/epidemiology ; Hand-Foot Syndrome/etiology ; Humans ; Incidence ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Paraneoplastic Polyneuropathy/epidemiology ; Paraneoplastic Polyneuropathy/etiology ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery
SCR Protocol :
XELOX
Czasopismo naukowe
Tytuł :
Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Autorzy :
Lee HW; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Seong SJ; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Kang WY; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Ohk B; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Gwon MR; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Kim BK; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Cho S; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Cho K; Analytical Research Division, Biocore Co. Ltd., Seoul, Republic of Korea.
Sung YK; Department of R&D, Myungmoon Pharm. Co., Ltd., Seoul, Republic of Korea.
Yoon YR; Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.; Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Kim JG; Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, Kyungpook National University, Daegu, Republic of Korea.
Pokaż więcej
Źródło :
Drug design, development and therapy [Drug Des Devel Ther] 2019 Sep 03; Vol. 13, pp. 3127-3136. Date of Electronic Publication: 2019 Sep 03 (Print Publication: 2019).
Typ publikacji :
Clinical Trial; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antimetabolites, Antineoplastic/*pharmacokinetics
Antineoplastic Agents/*pharmacokinetics
Fluorouracil/*pharmacokinetics
Oxonic Acid/*pharmacokinetics
Pyridines/*pharmacokinetics
Stomach Neoplasms/*metabolism
Tegafur/*pharmacokinetics
Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/blood ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/blood ; Chromatography, Liquid ; Cross-Over Studies ; Drug Compounding ; Fluorouracil/administration & dosage ; Fluorouracil/blood ; Humans ; Oxonic Acid/administration & dosage ; Oxonic Acid/blood ; Pyridines/administration & dosage ; Pyridines/blood ; Republic of Korea ; Stomach Neoplasms/chemistry ; Tandem Mass Spectrometry ; Tegafur/administration & dosage ; Tegafur/blood ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
Autorzy :
Hashimoto I; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.; Department of Surgery, Yokohama City University, Yokohama, Japan.
Oue N; Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan.
Kimura Y; Advanced Medical Research Center, Yokohama City University, Yokohama, Japan.
Hiroshima Y; Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Hara K; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.; Department of Surgery, Yokohama City University, Yokohama, Japan.
Maezawa Y; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.; Department of Surgery, Yokohama City University, Yokohama, Japan.
Kano K; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Fujikawa H; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Aoyama T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.; Department of Surgery, Yokohama City University, Yokohama, Japan.
Numata M; Department of Surgery, Yokohama City University, Yokohama, Japan.
Yamada T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Tamagawa H; Department of Surgery, Yokohama City University, Yokohama, Japan.
Yamamoto N; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Ogata T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Shiozawa M; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Morinaga S; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Rino Y; Department of Surgery, Yokohama City University, Yokohama, Japan.
Yasui W; Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan.
Masuda M; Department of Surgery, Yokohama City University, Yokohama, Japan.
Miyagi Y; Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Oshima T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Oct; Vol. 40 (10), pp. 5815-5821.
Typ publikacji :
Journal Article
MeSH Terms :
Prognosis*
Biomarkers, Tumor/*genetics
Stomach Neoplasms/*drug therapy
Zinc Finger Protein GLI1/*genetics
Aged ; Aged, 80 and over ; Disease-Free Survival ; Drug Combinations ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Male ; Neoplasm Staging ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe
Tytuł :
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Autorzy :
Kang YK; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Chin K; Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Chung HC; Division of Medical Oncology, Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
Kadowaki S; Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan.
Oh SC; Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Nakayama N; Department of Gastroenterology, Kanagawa Cancer Centre, Kanagawa, Japan.
Lee KW; Division of Haematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Hara H; Department of Gastroenterology, Saitama Cancer Centre, Saitama, Japan.
Chung IJ; Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, South Korea.
Tsuda M; Department of Gastroenterological Oncology, Hyogo Cancer Centre, Hyogo, Japan.
Park SH; Department of Medicine, Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hosaka H; Department of Gastroenterology, Gunma Prefectural Cancer Centre, Gunma, Japan.
Hironaka S; Clinical Trial Promotion Department, Chiba Cancer Centre, Chiba, Japan.
Miyata Y; Department of Medical Oncology, Saku Central Hospital Advanced Care Centre, Nagano, Japan.
Ryu MH; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Baba H; Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Hyodo I; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Boku N; Division of Gastrointestinal Medical Oncology, National Cancer Centre Hospital, Tokyo, Japan. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Aug; Vol. 21 (8), pp. 1045-1056. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Stomach Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Drug Combinations ; Female ; Humans ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies